1 / 24

Everolimus Treatment in Romanian Children with Tuberous Sclerosis: National Conference Results

Explore the results of Everolimus treatment on epilepsy in Romanian children with Tuberous Sclerosis Complex. Learn about dosage, monitoring, response, and potential benefits of this therapy from the XXIV-th National Conference of the Romanian Society Against Epilepsy.

lynettel
Download Presentation

Everolimus Treatment in Romanian Children with Tuberous Sclerosis: National Conference Results

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. The XXIV-th National Conference of The Romanian Society Against Epilepsy Results of Everolimus treatment on epilepsy in romanian children patients with Tuberous Sclerosis Complex Madalina Leanca¹´², Carmen Burloiu², Diana Barca²´³, Oana Tarta-Arsene²´³, Ioana Minciu ²´³Catrinel Iliescu²´³, Niculina Butoianu²´³, Cristina Pomeran¹´²´³, Rodica Gherghiceanu2,Alice Dica¹´², Carmen Sandu¹´²´³, Dana Craiu²´³ ¹ Romanian foundation of neurology and epileptology RONEP -Bucharest, Romania ² Child Neurology Clinic of “Alexandru Obegia” Hospital– Bucharest, Romania ³ Pediatric Neurology, "Carol Davila" University of Medicine – Bucharest, Romania

  2. The XXIV-th National Conference of The Romanian Society Against Epilepsy NATIONAL HEALTH PROGRAMME – RARE DISEASE TUBEROUS SCLEROSIS COMPLEX CHILD NEUROLOGY • ROMANIA STARTED NOV 2014 ADULT NEUROLOGY ADULT NEPHROLOGY

  3. The XXIV-th National Conference of The Romanian Society Against Epilepsy Indication for treatment with EVEROLIMUS • SEGA (SubependymalGiant Cell Astrocytoma ) associate TSC (neurology, child neurology) • RENAL ANGIOMYOLIPOMA associate TSC (nephrologist, urologist )

  4. The XXIV-th National Conference of The Romanian Society Against Epilepsy EVEROLIMUS – mTOR inhibitor • Initial dose – 4,5 mg/square meter • The dose is increased gradually seric concentration 3-15 ng/ml • Measuring serum concentration • 2 weeks of treatment started • After stabilization • Every 3-6 months • After any change in dose/ pharmaceutical form • After initiating therapy with inhibitors or inducers of CYP3A4

  5. The XXIV-th National Conference of The Romanian Society Against Epilepsy SEGA monitoring response to treatment • Measuring SEGA volume – every 3 months after treatment initiation • Imaging tests – cerebral MRI: • Every 3 months in the first year of treatment • Every 6 months if SEGA >1 cm • Every 12 months after second year of treatment

  6. The XXIV-th National Conference of The Romanian Society Against Epilepsy Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study Jacqueline A French, John A Lawson, ZuhalYapici, Hiroko Ikeda, TilmanPolster, RimaNabbout, Paolo Curatolo, Petrus J de Vries, Dennis J Dlugos, Noah Berkowitz, Maurizio Voi, SeverinePeyrard, Diana Pelov, David N Franz Lancet 2016; 388: 2153–63 Published Online September 6, 2016 http://dx.doi.org/10.1016/ S0140-6736(16)31419-2

  7. The XXIV-th National Conference of The Romanian Society Against Epilepsy ROMANIAN RESULTS

  8. The XXIV-th National Conference of The Romanian Society Against Epilepsy 13 PATIENTS FOLLOW UP 2 YEARS(NOV 2014-NOV 2016) 1 ADULT IUN2016 12 CHILDREN 10 CHILDREN 2 CHILDREN REFUSE TREATMENT

  9. The XXIV-th National Conference of The Romanian Society Against Epilepsy

  10. The XXIV-th National Conference of The Romanian Society Against Epilepsy MEDIAN AGE 10 YEARS

  11. The XXIV-th National Conference of The Romanian Society Against Epilepsy

  12. The XXIV-th National Conference of The Romanian Society Against Epilepsy ONSET SEIZURES AGE (MO)

  13. The XXIV-th National Conference of The Romanian Society Against Epilepsy

  14. The XXIV-th National Conference of The Romanian Society Against Epilepsy ANTIEPILEPTIC THERAPY AT ONSET

  15. The XXIV-th National Conference of The Romanian Society Against Epilepsy SEIZURE

  16. The XXIV-th National Conference of The Romanian Society Against Epilepsy TYPE OF SEIZURE BEFORE VOTUBIA EXIST 3 Lancet 2016; 388: 2153–63 Published Online September 6, 2016 http://dx.doi.org/10.1016/ S0140-6736(16)31419-2

  17. The XXIV-th National Conference of The Romanian Society Against Epilepsy NUMBER OF AED EXIST 3 Lancet 2016; 388: 2153–63 Published Online September 6, 2016 http://dx.doi.org/10.1016/ S0140-6736(16)31419-2

  18. The XXIV-th National Conference of The Romanian Society Against Epilepsy AED

  19. The XXIV-th National Conference of The Romanian Society Against Epilepsy ADVERSE EVENTS

  20. The XXIV-th National Conference of The Romanian Society Against Epilepsy NUMBER OF SEIZURE PER MONTH

  21. The XXIV-th National Conference of The Romanian Society Against Epilepsy 9 CHILDREN 5 CHILDREN 4 CHILDREN

  22. The XXIV-th National Conference of The Romanian Society Against Epilepsy • Everolimus effective treatment option not only for SEGA and AML, but also for TSC-related epilepsies. • Everolimus was well tolerated, with adverse effects similar to those reported in previous studies. • TAKE HOME MESSAGE

  23. The XXIV-th National Conference of The Romanian Society Against Epilepsy • Everolimus is effective and safe in infants and young children with epilepsy and SEGA associated with TSC • Everolimus can be a potential disease modifying therapy for TSC • TAKE HOME MESSAGE

  24. The XXIV-th National Conference of The Romanian Society Against Epilepsy i THANK YOU !!!

More Related